Literature DB >> 34043125

MiR-145 suppresses the motility of prostate cancer cells by targeting cadherin-2.

Huixuan Zeng1, Yishan Huang2, Qiuling Liu3, Hongjiao Liu4, Tianzhu Long4, Cairong Zhu5, Xiaoping Wu6.   

Abstract

Metastasis is the main cause of poor prognosis in the advanced prostate cancer in clinic. Accumulating evidences have proposed that cell motility greatly contributes to the multiple steps of the metastatic process. MicroRNA-145 (miR-145) has been found to be downregulated in prostate cancer and serve as a putative tumor suppressor via decrease of cell growth and augmentation of cell death; however, the effects and the underlying mechanisms of miR-145 in prostate cancer cell motility have not been completely clarified. In the current study, we first demonstrated that miR-145 exerted inhibitory effects on the aggressive phenotype of the prostate cancer cells. Based on the bioinformatics analysis of the putative target genes of miR-145, we further experimentally identified a novel mechanism of miR-145 suppressing the aggressive phenotype of prostate cancer cells via directly targeting cadherin-2 (CDH2) protein translation. Re-expression of CDH2 could rescue miR-145-triggered cell migration and invasion defects. Our results suggested that miR-145 suppressed the motility of prostate cancer cells via post-transcriptional downregulation of CDH2 expression, and miR-145-CDH2 pair might serve as a potential target for intervention of prostate cancer metastasis.

Entities:  

Keywords:  Cadherin-2; MiR-145; Motility; Prostate cancer

Year:  2021        PMID: 34043125     DOI: 10.1007/s11010-021-04188-0

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  44 in total

Review 1.  Cadherin recognition and adhesion.

Authors:  Deborah Leckband; Sanjeevi Sivasankar
Journal:  Curr Opin Cell Biol       Date:  2012-07-06       Impact factor: 8.382

Review 2.  Cadherin-mediated cell-cell adhesion and signaling in the skeleton.

Authors:  Pierre J Marie; Eric Haÿ; Dominique Modrowski; Leila Revollo; Gabriel Mbalaviele; Roberto Civitelli
Journal:  Calcif Tissue Int       Date:  2013-05-09       Impact factor: 4.333

3.  Silencing of LASS2/TMSG1 enhances invasion and metastasis capacity of prostate cancer cell.

Authors:  Xiaoyan Xu; Beiying Liu; Pengcheng Zou; Yan Zhang; Jiangfeng You; Fei Pei
Journal:  J Cell Biochem       Date:  2014-04       Impact factor: 4.429

Review 4.  Adjuvant and Salvage Radiotherapy after Radical Prostatectomy in Prostate Cancer Patients.

Authors:  Giorgio Gandaglia; Alberto Briganti; Noel Clarke; R Jeffrey Karnes; Markus Graefen; Piet Ost; Anthony Laurence Zietman; Mack Roach
Journal:  Eur Urol       Date:  2017-02-08       Impact factor: 20.096

Review 5.  New technologies and techniques for prostate cancer focal therapy.

Authors:  Estefanía Linares-Espinós; Arie Carneiro; Juan I Martínez-Salamanca; Fernando Bianco; Adalberto Castro-Alfaro; Xavier Cathelineau; Massimo Valerio; Rafael Sanchez-Salas
Journal:  Minerva Urol Nefrol       Date:  2018-04-16       Impact factor: 3.720

6.  Global cancer statistics, 2012.

Authors:  Lindsey A Torre; Freddie Bray; Rebecca L Siegel; Jacques Ferlay; Joannie Lortet-Tieulent; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2015-02-04       Impact factor: 508.702

Review 7.  Aberrant N-cadherin expression in cancer.

Authors:  Zhan-Qi Cao; Zhi Wang; Ping Leng
Journal:  Biomed Pharmacother       Date:  2019-08-12       Impact factor: 6.529

Review 8.  Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations.

Authors:  E David Crawford; Axel Heidenreich; Nathan Lawrentschuk; Bertrand Tombal; Antonio C L Pompeo; Arturo Mendoza-Valdes; Kurt Miller; Frans M J Debruyne; Laurence Klotz
Journal:  Prostate Cancer Prostatic Dis       Date:  2018-08-21       Impact factor: 5.554

9.  New Screening Test Improves Detection of Prostate Cancer Using Circulating Tumor Cells and Prostate-Specific Markers.

Authors:  Karin Ried; Tasnuva Tamanna; Sonja Matthews; Peter Eng; Avni Sali
Journal:  Front Oncol       Date:  2020-04-23       Impact factor: 5.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.